- Home
- MTDR vs RYTM Comparison
MTDR vs RYTM Comparison
Compare MTDR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTDR | RYTM |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.4B |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MTDR | RYTM |
|---|---|---|
| Price | $41.06 | $111.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $62.60 | ★ $127.31 |
| AVG Volume (30 Days) | ★ 1.4M | 966.4K |
| Earning Date | 10-21-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.24 | N/A |
| Revenue | ★ $3,556,751,000.00 | $174,334,000.00 |
| Revenue This Year | $14.79 | $47.34 |
| Revenue Next Year | $1.05 | $57.18 |
| P/E Ratio | $6.55 | ★ N/A |
| Revenue Growth | 14.75 | ★ 54.92 |
| 52 Week Low | $35.19 | $45.91 |
| 52 Week High | $64.05 | $122.20 |
Technical Indicators
Market Signals| Indicator | MTDR | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 55.90 |
| Support Level | $41.02 | $109.99 |
| Resistance Level | $43.11 | $115.05 |
| Average True Range (ATR) | 1.37 | 5.26 |
| MACD | -0.31 | 0.71 |
| Stochastic Oscillator | 6.51 | 50.49 |
Price Performance
Historical ComparisonAbout MTDR Matador Resources Company
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.